Zenas BioPharma, Inc. (ZBIO) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Securities class action litigation represents a material ongoing risk for Zenas BioPharma, Inc., as exemplified by the putative class action filed in April 2025 related to its IPO and subsequent amended complaint and motion to dismiss. This type of litigation can impose substantial legal costs, increase D&O insurance premiums, and divert management attention, thereby negatively affecting its operating results, liquidity, and overall financial condition.
Overall, Wall Street has a Strong Buy consensus rating on ZBIO stock based on 4 Buys and 1 Hold.
To learn more about Zenas BioPharma, Inc.’s risk factors, click here.